GCBiopharma said on the 24th that the Hunter syndrome treatment Hunterase IV received marketing authorization in India and Taiwan. Hunter syndrome is a rare disease caused by an enzyme deficiency. Patients experience a deformity with a protruding forehead and die before age 30.
In Taiwan, Hunterase ICV, which administers the drug directly into the ventricles by inserting the head into a device, also received marketing authorization. Seventy percent of Hunter syndrome patients have accompanying central nervous system damage. By addressing the issue that existing injectable drugs may not cross the blood-brain barrier, it improved treatment efficacy.
The company has secured the markets of India and Taiwan following Japan, China, and Malaysia. In particular, India has growth potential because the proportion of patients receiving Hunter syndrome treatments has been low.
Lee Jae-u, GC Biopharma head of R&D, said the company "will help improve patients' quality of life."